Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Link Established Between Active Disease/ICU Deferral and COVID-19 Mortality in AML, ALL, and MDS

December 12, 2021
By Gina Mauro
Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

Investigators noted that patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were more likely to experience COVID-19 mortality vs non-cancer patients.

Patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) who contracted COVID-19 were found to have higher mortality rate vs patients without cancer, according to data from the American Society of Hematology Research Collaborative (ASH RC) Data Hub for Hematology.

The overall mortality rate from COVID-19 in the cohort of 257 patients with AML/ALL/MDS was 21%. Sixty percent of patients overall were hospitalized for COVID-19 infection; 1% of patients who died did not require hospitalization for COVID-19 compared with 34% who did. In patients who went to the intensive care unit (ICU), the mortality rate was 68%.

Additionally, the findings, which were presented during the 2021 American Society of Hematology Annual Meeting, indicated that patients with both active disease and neutropenia at diagnosis were more likely to experience severe COVID-19 infection. However, those with active disease were not found to have increased mortality from the virus.

“The 2 factors that did impact COVID-19 mortality was having a primary disease prognosis of less than 6 months and deferral of ICU,” lead study author Pinkal Desai, MD, an assistant professor of medicine at Weill Cornell Medical College and assistant attending physician at NewYork-Presbyterian Hospital, said in a press briefing during the meeting. “Among hospitalized patients only, those with a pre–COVID-19 prognosis of less than 6 months and ICU deferral had higher COVID-19 mortality.”

Data are currently lacking on predictors of severe infection and outcomes with COVID-19 in patients with AML, ALL, and MDS. However, it is believed that those with active disease may experience poorer outcomes because of cytopenias and their overall prognosis. Additionally, Pinkal noted that single-center studies have demonstrated higher rates of COVID-19 infection severityand mortalityin patients with acute leukemia.

With the ASH RC Data Hub for Hematology, investigators sought to identify risk factors for severe COVID-19 infection and mortality in patients with AML, ALL, and MDS by utilizing the ASH RC COVID-19 Registry for Hematology.

The registry comprises the features and outcomes of confirmed or presumptive COVID-19 diagnoses in adult patients with ongoing or a history of hematologic disorders. Data collection was opened internationally on April 1, 2020, through a platform hosted by Prometheus Research, with data regularly updated on the ASH website.

Investigators analyzed patient characteristics, outcomes, and predictors, and stratification factors included disease status (active initial diagnosis vs relapsed/refractory vs remission) and type of hematologic cancer; variables were age, comorbidities, type of hematologic cancer (AML, ALL, or MDS), neutrophil and lymphocyte count, and active treatment at time of COVID-19 diagnosis. COVID-19 severity was considered mild (no hospitalization), moderate (hospitalization), or severe (ICU admission).

The primary end point of the research was mortality from COVID-19; COVID-19 severity served as a secondary end point.

Data comprised 257 patients overall with AML (n = 135; 53%), ALL (n = 82; 32%), and MDS (n = 40; 16%); 46% of patients were in remission and 44% had active disease; 10% of patients had unknown status. Nearly half (49%) of patients were younger than 60 years, 55% were male, and most patients (74%) had a major comorbidity. Seventy-five percent of patients had received systemic therapy in the previous year, and 72% had an estimated prognosis of more than 6 months. Also, most patients (78%) did not have deferred ICU.

In multivariable analyses, results showed that patients with active disease were found to be independently associated with severe COVID-19 (odds ratio [OR], 2.23; 95% CI, 1.18-4.29; P = .014). Furthermore, having neutropenia at diagnosis was also an independent association with severe COVID-19 (OR, 4.00; 95% CI, 2.24-10.60; P <.0001).

Additionally, in patients who had severe COVID-19, 67% had active disease compared with 33% who were in remission. In non-severe COVID-19 cases, 43% of patients had active disease and 57% of patients were in remission.

The variables associated with mortality among hospitalized patients with ALL/AML/MDS who had COVID-19 were having an estimated pre–COVID-19 diagnosis from the primary disease as less than 6 months (OR, 6.49; 95% CI, 2.12-22.57; P <.001) and having deferred ICU status (OR, 4.12; 95% CI, 1.53-11.63; P = .005).

“If desired by patients, aggressive support for hospitalized patients with COVID-19 is appropriate regardless of remission status,” Pinkal concluded.

Reference

Desai P, Goldberg AG, Anderson KC, et al. Clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 infection: report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. Presented at: 2021 ASH Annual Meeting & Exposition; December 10-14, 2021; Atlanta, GA. Abstract 280.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Related Content

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Roman Fabbricatore
July 1st 2025
Article

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Gina Mauro
June 30th 2025
Article

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

68Ga-NODAGA-LM3 May Effectively Evaluate Small Cell Lung Cancer Responses

Russ Conroy
June 28th 2025
Article

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.


Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Related Content

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Roman Fabbricatore
July 1st 2025
Article

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Gina Mauro
June 30th 2025
Article

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

68Ga-NODAGA-LM3 May Effectively Evaluate Small Cell Lung Cancer Responses

Russ Conroy
June 28th 2025
Article

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.


Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.